The genetic toxicology testing market involves assessment of potential genetic damage caused by pharmaceuticals, chemicals, and other product candidates during drug development. Genetic toxicology testing helps identify potential human carcinogens and prevent future health issues. It utilizes in vitro tests using microorganisms or cultured mammalian cells, and in vivo animal tests to detect damage to DNA caused by test agents. Next-generation sequencing (NGS) allows evaluation of genetic damage at a much higher resolution and lower cost compared to traditional techniques.

The Global Genetic Toxicology Testing Market is estimated to be valued at US$ 1.41 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period from 2024 to 2031.

Key Takeaways
Key players operating in the genetic toxicology testing are Genetic Toxicology Testing Market, By Type (In Vitro and In Vivo), By Product (Reagents, Consumables, Assays, and Services), By End User (Contract Research Organizations, Pharmaceutical Companies, Chemical Companies, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa).

Major opportunities lie in increased toxicology testing for environmental chemicals, agrochemicals, and industrial compounds. Next-generation sequencing has enabled more comprehensive assessment of genetic damage at a fraction of the cost, driving its adoption across pharmaceutical and chemical industries.

The Genetic Toxicology Testing Market Size in genetic testing, such as next-generation sequencing is allowing more holistic understanding of genomic alterations caused by potential toxins. NGS produces millions of reads at high accuracy, detecting even low levels of genetic damage that may be missed by conventional methods. This is expected to significantly improve risk assessment process.

Get More Insights On, Genetic Toxicology Testing Market